Three patients were treated with imatinib, erlotinib, and vemurafenib on the basis of an Asp572Gly KIT mutation (lung cancer), an EGFR amplification (cervical cancer), and a Val600Glu BRAF mutation (colorectal cancer), respectively (Table 2). Here, EGFR is linked to cervical cancer.